Searched for
NOVONIX
Trump's tariff threat spurs auto suppliers to rethink production plansThese tariffs could range up to 60%, significantly affecting the cost-effectiveness of auto parts from lower-cost markets, particularly Chi...- Trump's tariff threat spurs auto suppliers to rethink production plansGlobal auto suppliers are preparing to move production closer to the US due to potential high tariffs by President-elect Donald Trump. This...
- Australia's Novonix inks deal to supply synthetic graphite to Volkswagen-founded PowerCoNovonix said its Riverside facility, located in Chattanooga, Tennessee, is expected to begin its commercial production in 2025, targeting o...
- Synthetic graphite for EV batteries: Can the West crack China's code?New investments in the United States and Europe are aiming to challenge China's dominance in the graphite market, a key ingredient in elect...
- Soaring battery costs fail to cool electric vehicle salesThis year, EV demand has stayed strong even as the average cost of lithium-ion battery cells soared to an estimated $160 per kilowatt-hour ...
- Soaring battery costs fail to cool electric vehicle salesThis year, EV demand has stayed strong even as the average cost of lithium-ion battery cells soared to an estimated $160 per kilowatt-hour ...
- Tech and banks drag Australian shares lower; Ardent Leisure soarsThe S&P/ASX 200 index closed 0.63% lower at 7442.8 points, extending losses for the second straight session.
- Australian shares end lower as global rate hike bets firmThe S&P/ASX 200 fell as much as 1.2% during the session, but pared some losses to close 0.5% lower at 7490.1 points, in tandem with global ...
- Australian shares close lower after China cenbank keeps rates unchangedThe S&P/ASX 200 index closed down 0.2% at 7,278.50, after rising 0.8% earlier in the session.
- Australian shares snap three days of falls, banks and tech lead reboundThe S&P/ASX 200 index closed 1% higher at 7,053.00, marking its best day since Feb. 16.
- Australian shares wind down for Christmas on a positive noteReports showed that U.S. drugmakers Merck and Pfizer's COVID-19 antiviral pills were effective against the variant, cheering investors ahea...
Load More
